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Lowell, MassachusettsABSTRACT The regulated ability of integrin aIIbb3 to bind fibrinogen plays a crucial role in platelet aggregation, adhesion, and
hemostasis. Employing an optical-trap-based electronic force clamp, we studied the thermodynamics and kinetics of aIIbb3-
fibrinogen bond formation and dissociation under constant unbinding forces, mimicking the forces of physiologic blood shear
on a thrombus. The distribution of bond lifetimes was bimodal, indicating that the aIIbb3-fibrinogen complex exists in two bound
states with different mechanical stability. The aIIbb3 antagonist, abciximab, inhibited binding without affecting the unbinding
kinetics, whereas Mn2þ biased the aIIbb3-fibrinogen complex to the strong bound state with reduced off-rate. The average
bond lifetimes decreased exponentially with increasing pulling force from ~5 pN to 50 pN, suggesting that in this force range
the aIIbb3-fibrinogen interactions are classical slip bonds. We found no evidence for catch bonds, which is consistent with
the known lack of shear-enhanced platelet adhesion on fibrinogen-coated surfaces. Taken together, these data provide impor-
tant quantitative and qualitative characteristics of aIIbb3-fibrinogen binding and unbinding that underlie the dynamics of platelet
adhesion and aggregation in blood flow.INTRODUCTIONIntegrins are ubiquitous transmembrane heterodimers that
mediate cell-matrix and cell-cell interactions (1). In plate-
lets, the most abundant integrin is aIIbb3 (GPIIb-IIIa or
CD41/CD61), a receptor for fibrinogen, von Willebrand
factor, fibronectin, and vitronectin that is required for
platelet aggregation (2). There are 60,000–80,000 copies
of aIIbb3 on the surface of unstimulated platelets (3), and
an additional intracellular granular pool of aIIbb3 becomes
available after platelet activation (4). The presence of a suffi-
cient number of aIIbb3 molecules on the platelet surface is
necessary to prevent hemorrhage, so congenital deficiency
of functional aIIbb3 results in the hemorrhagic disorder
Glanzmann’s thrombasthenia. Conversely, the formation
of aIIbb3-mediated intravascular platelet aggregates causes
myocardial infarction and stroke, so the ligand-binding
activity of aIIbb3 is strongly regulated (5,6).
To form hemostatically effective platelet plugs, aIIbb3-
ligand interactions must be sufficiently strong to withstand
the mechanical loads of blood flow, vascular wall stretching,
and clot retraction. Previous studies of the strength of
aIIbb3-ligand bonds using single-molecule forced
unbinding studies have suggested that there is mechanical
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0006-3495/11/01/0165/9 $2.00(7–14). Steered molecular dynamics simulations also have
shown that aIIbb3 activation or deactivation is likely
preceded by a force-induced conformational rearrangement
(15–17). Further, aIIbb3 and other integrins are thought to
play a central role in sensing and converting external
mechanical forces into intracellular perturbations, a process
termed molecular mechanotransduction (18–20).
A number of molecular complexes, including P-selectin-
PSGL-1 (21), GP1ba-von Willebrand factor (22), myosin-
actin (23), and FimH-mannose (24) display catch-bond
behavior, where bond stability increases with increasing
mechanical tension (25–27). This may also be the case for
integrins, since the integrin a5b1 was recently found to
display catch-bond behavior during its interaction with
a fragment of fibronectin (28). Nonetheless, there is as yet
no direct evidence that this is the case for integrins in
general.
Previously, we used optical-trap force spectroscopy to
show that the distribution of rupture forces between indi-
vidual aIIbb3 and fibrinogen molecules displays at least
two components that differ in kinetics, loading-rate depen-
dence, and susceptibility to aIIbb3 activation and inhibition
(11). Thus, the interaction of aIIbb3 and fibrinogen appears
to be a complex, multistep process that depends on the
conformational state of both aIIbb3 and fibrinogen, the
duration of their interaction, and environmental factors
such as externally applied shear force.
Here, we studied the factors responsible for the formation
of stable aIIbb3-fibrinogen complexes and tested the possi-
bility that aIIbb3 displays catch-bond behavior by quanti-
fying the lifetime of bonds between individual aIIbb3 anddoi: 10.1016/j.bpj.2010.11.019
166 Litvinov et al.fibrinogen molecules using an upgraded optical trap setup
that applies constant unbinding force to single-molecule
protein-protein complexes. We found that the distribution
of aIIbb3-fibrinogen bond lifetimes was bimodal, reflecting
the heterogeneous nature of the interactions and the pres-
ence of multistep binding/unbinding pathways. Further-
more, aIIbb3-fibrinogen complexes displayed classical
slip-bond behavior in a force range up to 50 pN without
signs of catch-bond formation. These data provide new
mechanistic insights into the dynamics of aIIbb3-fibrinogen
interactions that underlie the formation of platelet aggre-
gates in the bloodstream.MATERIALS AND METHODS
Modification of an optical trap to measure
receptor-ligand interactions at constant tensile
force
A custom-built optical trap, previously described in detail (11), was modi-
fied to measure individual ligand-receptor interactions under constant force
(Fig. 1). This system makes it possible to control the duration of compres-
sive contact between interacting surfaces, the magnitude of compressiveBiophysical Journal 100(1) 165–173force, and the magnitude of the tensile force during bond rupture. The
maximum tensile force is limited to ~100 pN. All experiments are con-
ducted at an average trap stiffness of 0.105 0.02 pN/nm. Force calibration
and trap stiffness are routinely confirmed by the Stokes’ force method (29).
LabVIEW software is used to control and record laser-beam deflection,
move the piezoelectric stage, and analyze data off-line.Measurement of aIIbb3-fibrinogen bond lifetimes
To measure the lifetime of aIIbb3-fibrinogen bonds, purified aIIbb3 dis-
solved in 20 mM HEPES buffer, pH 7.4 (150 mM NaCl, 30 mM n-octyl-
b-D-glucoside, and 1 mM CaCl2) was immobilized on stationary silica
pedestals 5 mm in diameter (Bangs Laboratories, Fishers, IN) anchored
with a thin layer of polyacrylamide to the bottom of a flow-through
chamber, as previously described (8,11). When Mn2þ was used to activate
aIIbb3, the integrin was pretreated with 1 mM MnCl2 for 30 min at 37
C
before it was immobilized in the presence of 1 mMMnCl2. Purified human
fibrinogen was covalently coupled to suspended carboxylate-modified
1.75-mm latex beads (Bangs Laboratories, Fishers, IN) using water-soluble
carbodiimide. Bovine serum albumin (BSA) was then used to block poten-
tial unoccupied protein-binding sites on the silica pedestals and latex beads.
Before each experiment, the flow-through chamber was equilibrated with
the working buffer (0.1 M HEPES buffer, pH 7.4, with 2 mg/ml BSA, 0.1%
Triton X-100, and 1 mM CaCl2 or 1 mM MnCl2) at room temperature.
Then, 1 ml of the fibrinogen-coated latex bead suspension (107 beads/ml)
in 50 ml of working buffer was flowed into the chamber containingFIGURE 1 (A) Simplified schematic drawing of the
optical trap setup equipped with a force clamp. Briefly,
the core of the optical trap is a Nikon Diaphot 300 inverted
microscope and a 100 1.3 NA Fluor lens combined with
an FCBar Nd/YAG laser (l¼ 1064 nm) with 4 W power in
continuous TEM-00 mode. A computer-operated two-
dimensional acousto-optical deflector (AOD) is used to
control the tilt of the incoming laser beam at the back focal
plane of the microscope objective, thereby altering the trap
position. Displacement of a latex bead from the trap
center, and consequently the force exerted by the trap on
the displaced bead, is measured with a back focal plane
quadrant detector. The voltage signal produced by the
photodiode can be calibrated in force units using the power
spectrum of Brownian motion of a trapped bead. The force
clamp consists of an analog feedback loop that adjusts the
trap position (AOD) relative to the center of the ligand-
coated latex bead so that the difference between the quad-
rant detector voltage (bead force) and a command signal is
kept nearly zero. The command signal is generated by
a digital-to-analog board under the control of a LabVIEW
program (National Instruments, Austin, TX). The
command is normally a square-wave voltage adjusted to
give positive and negative force amplitudes, frequency,
and duty cycle. (B) A bead oscillation cycle and portion
of a typical data trace of aIIbb3-fibrinogen interactions
under a constant tensile force. The bead motion cycle
has four parts: 1), approach of a bead to a pedestal;
2), bead-pedestal contact; 3), bonding under tensile force
(if a bond formed); and 4), the bead moving away. When
the command is positive, the ligand-coated bead is
compressed at constant force against a silica pedestal
coated with receptor protein. When the command is nega-
tive and no bond has formed during the compression, the
trap is stopped at a fixed distance from the pedestal. If,
however, a bond has formed, the trap maintains constant
tension throughout the lifetime of the ligand-receptor
bond (Fig. 1 B and Fig. S2).
Stability of Integrin-Fibrinogen Complex 167aIIbb3-coated pedestals. In control experiments, inhibitors of ligand
binding to aIIbb3 were added to the bead suspension before it was intro-
duced into the chamber.
The chamber containing fibrinogen-coated beads was then placed on
a microscope stage, a single bead was trapped by the laser, and the stage
was moved manually to bring an aIIbb3-coated pedestal within 1–2 mm
of the trapped bead. The microscope focus was adjusted so that the bead
and pedestal centers were the same distance from the coverslip surface.
Then, using the piezostage, the separation of pedestal and bead was reduced
in 100-nm or 10-nm steps until they touched each other. For measurements
of fibrinogen-aIIbb3 bonds with force spectroscopy, the position of the
optical trap was oscillated in a triangular waveform with oscillation
frequencies of 10 Hz and constant peak-to-peak amplitude of 800 nm.
For measurement of the bond lifetimes under a constant force, the feedback
loop controlled the bead force as a square wave with independent control of
the magnitude and duration of bead compression and tension. The compres-
sive force (both in force-clamp and ramp-force measurements) was in the
range 10–20 pN and the duration of contact in the constant-force experi-
ments was 0.5 s. The data were recorded from first contact and were digi-
tized at the rate of 2000 samples/s.
Several tens of pedestal-bead pairs, using aIIbb3 and fibrinogen from
different batches, were analyzed for each experimental condition. The
number of contacts recorded for each pedestal and bead pair depended on
the oscillation frequency and the incidence of binding events and was
collected for ~10 min to obtain a manageable file size. The binding/
unbinding events from individual files were summarized so that the total
number of bond-lifetime values observed at each experimental condition
varied from ~102 to 103. Bond lifetimes of <40 ms represented weak,
nonspecific interactions and were not susceptible to inhibition by eptifiba-
tide or abciximab or enhancement by Mn2þ. Bond-lifetime values were
sorted into a histogram and normalized by the total number of contacts.
The percentage of events in a particular bond-lifetime range (bin) represents
the probability density of a bond rupture in that range.Purification of functional aIIbb3 and fibrinogen
aIIbb3 was purified from detergent extracts of human platelets by affinity
chromatography, as described previously (30). Purified human fibrinogen
was purchased from HYPHEN BioMed (France). The polypeptide compo-
sition, purity, and potential oligomerization of the purified proteins were as-
sessed by SDS-polyacrylamide gel electrophoresis and transmission
electron microscopy using rotary shadowing with tungsten (31). The puri-
fied fibrinogen was 97% clottable with thrombin, confirming its purity and
activity. The ability of the purified fibrinogen to bind to aIIbb3 was
confirmed using rupture-force spectroscopy (8,11). The distribution of
rupture forces for fibrinogen bound to aIIbb3 corresponds to our previously
observed force spectra and demonstrates that at least 80% of the interac-
tions stronger than 20 pN were sensitive to the aIIbb3-specific inhibitor ep-
tifibatide (Fig. S4 in the Supporting Material) and therefore represent
specific aIIbb3-fibrinogen binding.Analysis of aIIbb3-fibrinogen bond lifetimes
and mapping the free energy landscape for
aIIbb3-fibrinogen bond rupture
The distribution of experimental bond lifetimes in this study was bimodal,
suggesting that the unbinding process can be modeled as multistep dissoci-
ations that follow complex paths through the free-energy landscape of the
interaction (32). Because the first portion of the bond-lifetime distribution
appeared to be a spontaneous and stochastic process, it was described using
a single-step kinetic model: LR/Lþ R, with an unbinding rate constant,
ku1, where LR denotes the fibrinogen-aIIbb3 (ligand-receptor) complex,
and L and R stand for fibrinogen and aIIbb3, respectively. Correspondingto this process, an exponential probability density function of the bond life-
times pu(t) is given by
puðtÞ ¼ ku1exp½ku1t: (1)
To analyze the second portion of the bond-lifetime distribution, we
applied a simple analytical model that provided reasonable fits for the
aIIbb3-fibrinogen dissociation data and modeled the conformational rear-
rangement of molecules during bond rupture with three phenomenological
parameters (33,34). This model was recently used successfully to describe
the mechanical unfolding of the all-b-sheet WW domain (33).
The major assumption underlying this model, an assumption consistent
withour previous experimental data (11), is that the externalmechanical force,
fext, experienced by the aIIbb3-fibrinogen system increases linearly with the
elongation of the complex, x ¼ ðfext=kspÞ, where ksp is a lumped spring
constant corresponding to the mechanical deformations of the aIIbb3-fibrin-
ogen complex. Here, x is a collective reaction coordinate, quantifying the
extent of the mechanochemical unbinding reaction for the aIIbb3-fibrinogen
complex and reflects the sum of the force-induced aIIbb3-fibrinogen bond
extension, as well as conformational changes, including straightening and
partial elongation of the integrin and fibrinogen molecules. Based on these
assumptions, the lifetime of more prolonged aIIbb3-fibrinogen interactions
can be described using a Brownian oscillator model (a harmonic oscillator
coupled to a stochastic environment). In this model, the force-induced disso-
ciation of the aIIbb3-fibrinogen complex can be described by the one-dimen-
sional Brownianmotion of the extension of theaIIbb3-fibrinogen complex, x,
in a harmonic potential,U ¼ kspx2=2 (34), undergoinggradual diffusion in the
direction of pulling force. The extension, x, is assumed to follow theLangevin
equation, zdx=dt ¼ kspx þ fext þ gðtÞ, where z is the friction constant, fext is
the pulling force, and gðtÞ is the Gaussian random force, which represents the
influence of the thermal environment surrounding the aIIbb3-fibrinogen
complex (kB is the Boltzmann constant and T is the temperature). Bond
rupture is assumed to occur when x reaches the critical elongation of the
complex, x. The corresponding cumulative distribution function of bond life-
times is given by (33)
PuðtÞ ¼ 1
2
Erfc
"
x  hxðtÞiﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2wðtÞp
#
; (2)
where Erfc[y] is the complementary error function (35),
hxðtÞi ¼ fext=kspð1 eku2tÞ is the average extension of the complex,
wðtÞ ¼ kBT=kspð1 e2ku2 tÞ is the width of the distribution and
ku2 ¼ ksp=z is the unbinding rate constant. The probability density function
of bond lifetimes is given by puðtÞ ¼ dPuðtÞ=dt. We used these equations to
describe strong aIIbb3-fibrinogen interactions in the absence and in the
presence of a specific aIIbb3 inhibitor, abciximab, or of the aIIbb3 acti-
vator Mn2þ (Fig. 2), and to resolve the critical extension of the receptor-
ligand complex, x, the spring constant, ksp, and the unbinding rate, ku2
(see Tables 2 and 3). Statistical analysis of the extracted parameters was
performed using the bootstrapping method (36).
In addition to an analysis of bond-lifetime distributions, we mapped the
average free-energy landscape for the force-induced dissociation of the
aIIbb3-fibrinogen complex using the Bell model (37) for the force depen-
dence of the average unbinding rate KuðfextÞ,
KuðfextÞ ¼ K0uexp

fextX
=kBT

; (3)
where K0u is the average force-free rate constant for unbinding, and X
 is the
distance from the bound state (LR) to the ensemble average transition state
for unbinding (the average interaction range). It is noteworthy that there can
be several bound states (LR1, LR2, etc.) or the forced unbinding might occur
through multiple unbinding pathways or might involve formation of inter-
mediate species. Therefore, ku and x
 values for different bound states or
unbinding pathways might not be equal to their ensemble averages, Ku
and X, respectively. The phenomenological parameters K0u and X
 wereBiophysical Journal 100(1) 165–173
FIGURE 2 Histograms of bond lifetimes for the aIIbb3-fibrinogen inter-
actions measured under a constant tensile force of fext ¼ 50 pN and contact
duration (interaction) T ¼ 0.5 s. The bond lifetimes in the absence (A) and
presence of 200 mg/ml abciximab, a specific aIIbb3 antagonist (B), or 1 mM
Mn2þ, an integrin activator (C), are compared with the theoretically derived
probability density functions of bond lifetimes (fitting curves) obtained
using Eq. 6. In the histograms, the bin size is obtained using an adaptive
approach to the optimal bandwidth selection (52). (Insets) Raw data traces
typical for each experimental condition represented in the figure.
TABLE 1 Differential effects of abciximab and Mn2þ on the
cumulative probabilities of short (t < 2s) and long (t > 2s)
interactions between aIIbb3 and fibrinogen
Probability of
short interactions
lasting <2 s
Probability of
long interactions
lasting >2 s
Fibrinogen þ Integrin (n ¼ 56) 0.195 0.12 0.0205 0.016
Fibrinogen þ Integrin þ
Abciximab (n ¼ 26)
0.085 0.06 0.00325 0.0054
Fibrinogen þ Integrin þ Mn2þ
(n ¼ 28)
0.285 0.18 0.0805 0.074
Numbers within a column are significantly different (p < 0.01).
168 Litvinov et al.determined from least-squares fits to the average bond-lifetime data. The
obtained value of K0u can be used to estimate the ensemble average energy
of unbinding, DU,
K0u ¼
Dksp
2pkBT
exp

 DU
kBT

; (4)
where D ¼ kBT=z is the diffusion constant.Biophysical Journal 100(1) 165–173RESULTS
Distribution of the aIIbb3-fibrinogen bond
lifetimes
When pedestals coated with aIIbb3 and beads coated with
fibrinogen were allowed to interact for 0.5 s, followed by
forced unbinding under a constant 50-pN tension, a wide
range of dissociation times (t), varying from milliseconds
to seconds, was observed (Fig. 2 A). In a series of control
experiments performed using untreated beads and pedestals
or replacing aIIbb3, fibrinogen, or both with inert
compounds, the durations of interactions were substantially
briefer (Table S1). The cumulative probability of aIIbb3-
fibrinogen interactions with bond lifetimes >0.04 s was
~20% (Table 1), and the probability of nonspecific interac-
tions in the control experiments was in the range 0.3–5.3%
(Table S1). In all cases, the low probability of events suggests
that the majority of the observed binding events were bimo-
lecular. Bond lifetimes of t < 0.04 s were likely due to
nonspecific interactions, since they were insensitive to
aIIbb3 inhibitors and activators. For bond lifetimes between
t> 0.04 s and t< 2 s, there was an exponentially decreasing
probability density, whereas for lifetimes of t> 2 s, therewas
a peak probability density at ~3 s. Thus, these results indicate
that there are two distinct aIIbb3-fibrinogen binding states,
one with lower and one with higher mechanical stability.
To evaluate the specificity of fibrinogen binding to
aIIbb3, the system was perturbed by adding either abcixi-
mab, the Fab fragment of a murine-human chimeric mono-
clonal antibody that inhibits fibrinogen binding to aIIbb3
(38), or Mn2þ, which shifts inactive integrins to their active
states by perturbing the conformation of their extracellular
domains (39). The detailed analysis of the cumulative
binding probabilities in the presence of abciximab shown
in Fig. 2 indicates that although abciximab reduced the
number of interactions lasting >2 s by sixfold, it only in-
hibited interactions lasting <2 s by ~40% (Table 1). These
experiments thus confirm that the longer- and shorter-dura-
tion interactions we measured result from the specific inter-
action of aIIbb3 with fibrinogen. However, they also
demonstrate that these interactions are differentially sensi-
tive to the inhibitory effect of abciximab.
Stability of Integrin-Fibrinogen Complex 169To test whether Mn2þ-induced aIIbb3 activation alters
the fibrinogen-binding characteristics of individual aIIbb3
molecules, we measured aIIbb3-fibrinogen bond lifetimes
in the presence of 1 mM MnCl2. In the presence of Mn
2þ,
the peak of the longer bond lifetimes shifted from ~3 s to
~6 s (Fig. 2 C). Further, Mn2þ also increased the cumulative
probability of interactions lasting <2 s by ~30% and the
number of interactions lasting >2 s by fourfold (Table 1).
It is noteworthy that in the presence of Mn2þ, the fraction
of active aIIbb3 molecules became substantially greater,
consistent with the notion that Mn2þ induces a structural re-
arrangement of aIIbb3 that enables it to bind fibrinogen.
Our results indicate that Mn2þ increases the mechanical
stability of the aIIbb3-fibrinogen complex as well.Kinetic and thermodynamic characteristics of the
force-induced dissociation of aIIbb3-fibrinogen
complexes
To obtain kinetic and thermodynamic parameters of the
aIIbb3-fibrinogen interaction, the dynamics of unbinding
were modeled using a two-state kinetic scheme,
LR1/
ku1
L þ R
k12Y
LR2/
ku2
L þ R
; (5)
where ku1 is the rate constant for unbinding for the short-
duration interactions (LR1), ku2 is the rate constant for
unbinding for the long-duration interactions (LR2), and k12
is the rate constant for the conformational transition
LR1/LR2. The probability density function of the
aIIbb3-fibrinogen bond lifetimes corresponding to the
kinetic scheme (Eq. 5) is given by
puðtÞ ¼ l1pu1ðtÞ þ l2pu2ðtÞ; (6)
where l1 and l2 are the populations of the bound-state LR1
and LR2, respectively (l1 þ l2 ¼ 1). As discussed in detail
inMaterials andMethods, an exponential probability density
function was used to model pu1ðtÞ, dissociation from the
short-duration state LR1, and the Brownian oscillator model
was used tomodel pu2ðtÞ, dissociation from the long-durationTABLE 2 Average forced unbinding characteristics from the Brown
states of the aIIbb3-fibrinogen complex
Control
LR1 LR2
Populations, l1 and l2 0.83 (0.04) 0.17 (0.04)
Unbinding rate constants, ku1 and ku2 (s
1) 3.06 (0.11) 0.25 (0.01)
Spring constant, ksp (pN/nm) — 12.00 (0.07)
Critical extension, x* (nm) — 2.46 (0.05)
Unbinding energy, kBT — 8.78 (0.41)
Analytical estimates of the mechanical, kinetic, and equilibrium parameters co
introduced in the Materials and Methods section. Numbers in parentheses are sstate LR2. Wewere able to estimate the kinetic parameters of
the model using Eq. 6 and numerically fit the computation-
ally derived distributions of bond lifetimes to the experimen-
tally obtained histograms of aIIbb3-fibrinogen bond
lifetimes in the absence or presence of abciximab as well
as in the absence or presence of Mn2þ (Fig. 2).
Using the two-step kinetic scheme to model the constant-
force experiments indicated that when aIIbb3 and fibrin-
ogen were allowed to interact for 0.5 s, the resulting
complex was found to be predominantly in the short-dura-
tion state, LR1, l1 ¼ 0.83 vs. l2¼ 0.17 for the long-duration
state, LR2, and with unbinding rate constants ku1 ¼ 3.06 s1
and ku2¼ 0.25 s1, respectively (Table 2). This result is
similar to the experimentally determined prevalence of
shorter (t < 2 s) and longer (t > 2 s) bond lifetimes shown
in Table 1. Further, the force-induced rupture of the long-
duration state, LR2, was characterized by a stiff molecular
spring (ksp¼ 12 pN/nm) and a large critical extension of
the complex (xu2¼ 2.46 nm) at which point the complex
falls apart (Table 2). This implies that dissociation of the
long-duration state, LR2, is associated with partial straight-
ening and/or extension of the aIIbb3 and/or fibrinogen
molecules. The presence of abciximab did not affect the
kinetics of aIIbb3-fibrinogen bond rupture, but rather
blocked formation of the long-duration state LR2, i.e.,
l1 ¼ 0.97 for LR1 versus l2 ¼ 0.03 for LR2 (Table 2).
Mn2þ destabilized the short-duration state (l1 ¼ 0.71 vs.
0.83 for control, p < 0.01) without significantly affecting
the kinetics of the aIIbb3-fibrinogen bond rupture from
LR1 (ku1 ¼ 2.84 s1 vs. 3.06 s1, p > 0.05). By contrast,
it enhanced the stability of long-duration binding (l2 ¼
0.29 vs. 0.17 in control, p < 0.001) and altered the kinetics
of the aIIbb3-fibrinogen bond rupture from this state by
increasing the critical extension of the complex, xu2, from
2.46 nm to 2.86 nm (p< 0.01) and by decreasing the kinetic
rate constant, ku2, from 0.25 s
1 to 0.189 s1 (p < 0.05)
(Table 2).
Model parameters, i.e., the molecular spring constants
(ksp) and the critical extensions (x

u2), were then used to esti-
mate the energy needed to dissociate aIIbb3 from fibrinogen
in the long-duration state, DUðLR2Þ ¼ kspx2u2=2. This
energy must be supplied to the complex to overcome the
transition-state barrier for unbinding. We found that atian oscillator model for the weak (LR1) and strong (LR2) bound
With abciximab With Mn2þ
LR1 LR2 LR1 LR2
0.97 (0.03) 0.03 (0.03) 0.71 (0.03) 0.29 (0.03)
3.38 (0.33) 0.25 (0.01) 2.84 (0.17) 0.189 (0.002)
— 12.02 (0.08) — 13.58 (0.08)
— 2.52 (0.04) — 2.86 (0.05)
— 9.20 (0.28) — 12.42 (0.53)
rrespond to a tensile force of fext ¼ 50 pN. The model and parameters are
tandard deviations.
Biophysical Journal 100(1) 165–173
170 Litvinov et al.room temperature (T ¼ 300 K), abciximab had no signifi-
cant effect on the energy required to dissociate aIIbb3 and
fibrinogen: DUðLR2Þ ¼ 8:78kBT or 21.9 kJ/mol in the
absence of abciximab, and 9.2kBTor 23.2 kJ/mol in the pres-
ence of abciximab (p > 0.05). However, Mn2þ ions
increased the unbinding energy to DUðLR2Þ ¼ 12:42kBT
or 30.8 kJ/mol (p < 0.05) (Table 2).Force dependence of the force-induced
dissociation
The distribution of dissociation times for aIIbb3-fibrinogen
bonds is strongly dependent on the applied constant tension
(Fig. 3 and Fig. S6). The weighted average of the lifetimes
of aIIbb3-fibrinogen bonds decreased exponentially as
tensile force was increased in the range 5–50 pN (Fig. 3).
The average lifetimes were fit using the Bell model (Eq. 3
and Fig. 3, solid line) with K0u¼ 0.052 s1 and
X ¼ 0.28 nm. Because the force-induced dissociation of
the aIIbb3-fibrinogen complex is dominated by the rupture
of the aIIbb3-fibrinogen bond from the weaker bound state,
LR1 (Fig. 2 A), these values are more characteristic of the
force-free unbinding rate constant (k0u1) and the critical
extension (xu1) for the weak bound (short-duration) state
(LR1), i.e., k
0
u1zK
0
u¼ 0.052 s1 and xu1zX ¼ 0.28 nm.
Using Eq. 4, we also estimated the ensemble average energy
of dissociation of the aIIbb3-fibrinogen complex, which is
roughly equal to the energy of dissociation of the weak
bound state, LR1, i.e., DUzDUðLR1Þ. We found that
DUðLR1Þz0:3kBT (0.75 kJ/mol), confirming the weak
binding of aIIbb3 and fibrinogen in LR1.
To test whether the bimodal nature of bond lifetimes
persists at different unbinding forces and to quantitativelyFIGURE 3 The effect of tensile force fext on the weighted average of
aIIbb3-fibrinogen bond lifetimes, t, shown on a semilogarithmic scale.
The least-squares fit of the experimental data points for the aIIbb3-fibrin-
ogen bond lifetimes (black squares) with the theoretical dependence of
the bond lifetimes on pulling force, htðfextÞi(solid line), was used to estimate
the kinetic parameters underlying the force-induced rupture of single bonds
between the fibrinogen ligands and the aIIbb3 receptors summarized in the
main text.
Biophysical Journal 100(1) 165–173assess the mechanical compliance of the aIIbb3-fibrinogen
complex in response to variable tension, we used the
two-state kinetic scheme to analyze the bond-lifetime
distributions obtained at the different tensile forces
fext ¼10–20 pN, fext ¼20–40 pN, and fext ¼50 pN
(Fig. S6). The model parameters obtained for the different
values of fext are summarized in Table 3. These were also
extrapolated linearly to fext ¼ 0. Several clear trends in the
force dependence of the model parameters are apparent.
First, the population l2 increases (l2 ¼ 0.17 < 0.28 <
0.38 < 0.42) and the population l1 decreases (l1 ¼
0.83 > 0.72 > 0.62 > 0.58) with decreasing force. This
implies that at lower forces, the aIIbb3-fibrinogen complex
in state LR2 is more stable than at higher forces and that the
conformational transition, LR1/LR2, occurs on an experi-
mental timescale of a few seconds. Using the contact dura-
tion of 0.5 s, we can estimate the rate constant k12 as ~1/T ¼
2.0 s1. Second, the unbinding rate constants for LR1 and
LR2 increase with unbinding force (ku1 ¼ 1.1 < 1.28 <
1.64 < 3.06 s1 and ku2 ¼ 0.15 < 0.16 < 0.207 <
0.25 s1, respectively), implying that both the weaker and
stronger aIIbb3-fibrinogen interactions represent classical
slip bonds without a catch-to-slip bond transition. Third,
the molecular spring constant ksp for the LR2 complex
increases with force (7.5 < 8.0 < 9.3 < 12.0 pN/nm),
implying that the aIIbb3-fibrinogen complex becomes
stiffer when pulled harder. Last, the critical extension, x*,
for the LR2 state increases with force (1.78 < 1.98 <
2.26 < 2.46 nm), indicating that the position of the transi-
tion state for the force-driven dissociation shifts toward
the unbound state. Thus, the forced unbinding reactions at
higher forces are likely coupled to short-scale conforma-
tional transitions, presumably partial elongation of the inter-
acting species, molecular straightening, and alignment
along the direction of pulling force. This is consistent
with the observed increase of the unbinding energy with
force (2.9 < 3.78 < 5.73 < 8.78 kBT).DISCUSSION
Fibrinogen binding to the integrin aIIbb3 is essential for the
platelet-matrix and platelet-platelet cohesion that occurs in
dynamic high-shear conditions in vivo. Thus, studies of
aIIbb3-fibrinogen forced unbinding are physiologically
relevant (40,41). Previously, we studied fibrinogen binding
to aIIbb3 using optical-trap-based rupture-force spectros-
copy where the rupture force is ramped to quantify the
binding strength of individual aIIbb3 and fibrinogen mole-
cules under different experimental conditions, using either
purified proteins or immobilized living platelets (8,11,13).
We found that fibrinogen binding to aIIbb3 is a complex,
time-dependent, multistep process during which the
strength of the bond between aIIbb3 and fibrinogen appears
to progressively increase. Here, we employed an optical-
trap-based force clamp to study the interaction of purified
TABLE 3 Kinetic and thermodynamic characteristics for the weak (LR1) and strong (LR2) bound states of the aIIbb3-fibrinogen
complex at different tensile forces (fext)
fext ¼ 50 pN fext ¼ 20–40 pN fext ¼ 10–20 pN fext ¼ 0 pN*
LR1 LR2 LR1 LR2 LR1 LR2 LR1 LR2
Populations, l1 and l2 0.83 (0.04) 0.17 (0.04) 0.72 (0.03) 0.28 (0.03) 0.62 (0.02) 0.38 (0.02) 0.58 0.42
Unbinding rate constants, ku1 and ku2 (s
1) 3.06 (0.11) 0.25 (0.01) 1.64 (0.11) 0.207 (0.008) 1.28 (0.08) 0.16 (0.01) 1.1 0.15
Spring constant, ksp (pN/nm) — 12.00 (0.07) — 9.30 (0.45) — 8.00 (0.71) — 7.5
Critical extension, x* (nm) — 2.46 (0.05) — 2.26 (0.09) — 1.98 (0.13) — 1.78
Unbinding energy, kBT — 8.78 (0.41) — 5.73 (0.37) — 3.78 (0.41) — 2.9
Parameters are introduced in the Materials and Methods section. Numbers in parentheses are standard deviations.
*The parameters for fext ¼ 0 pN were determined by linear extrapolation.
Stability of Integrin-Fibrinogen Complex 171aIIbb3 with fibrinogen under constant tensile force. This
enabled us to derive equilibrium thermodynamic and kinetic
parameters directly from the bond-lifetime measurements.
To ensure that the majority of the observed rupture events
were due to single aIIbb3-fibrinogen bonds, surface-coating
conditions were tuned to keep protein density low. Thus, the
frequency of binding events comprised <30% of total inter-
face contacts (Fig. S4 A), and <90% of the rupture events
occurred in a single step. Further, we found that eptifibatide,
a small-molecule aIIbb3-specific inhibitor of fibrinogen
binding to platelets, reduced the binding probability sixfold,
indicating that most rupture-force events resulted from
aIIbb3-fibrinogen binding (Fig. S4 B).
Most rupture force measurements were performed at
a tensile force fext ¼ 50 pN, which is within the range of
hydrodynamic forces exerted on single integrin-fibrinogen
bonds during arterial thrombosis (42). We found that the
bond-lifetime histograms for fibrinogen bound to aIIbb3
(Fig. 2 A) had a bimodal distribution, implying two bound
states of the aIIbb3-fibrinogen complex. The first state
was composed of shorter-lifetime interactions, t < 2 s,
with an unbinding rate constant ku1¼ 3.06 s1 and was asso-
ciated with an exponential probability distribution. The
second state had a broader Gaussian-like distribution and
was composed of interactions with prolonged lifetimes,
t > 2 s, and an ~10-fold-lower unbinding rate constant,
ku2¼ 0.25 s1.
The two bound states, designated LR1 and LR2, also
differed in their dissociation energy, their stability against
the mechanical perturbation, and their susceptibility to inhi-
bition and activation, suggesting that they correspond to the
low- and high-affinity aIIbb3-fibrinogen interactions
discovered earlier in bulk experiments (43). Bond lifetimes
of <2 s were found to be less perturbed by abciximab,
a specific aIIbb3 antagonist, whereas bond lifetimes >2 s
were suppressed severalfold. Moreover, the longer-duration
interactions were found to be more sensitive to activation
with Mn2þ ions (Table 1). This resulted in a substantial
increase in the frequency of fibrinogen binding to aIIbb3,
likely due to an increased fraction of molecules in the
high-affinity form, as well as increased stability of the
aIIbb3-fibrinogen complex. Indeed, in the presence of
Mn2þ, the population of LR2 increased from l2 ¼ 0.17 tol2 ¼ 0.29 (p < 0.001) and the unbinding rate constant for
the high-affinity aIIbb3-fibrinogen interactions decreased
from ku2¼ 0.25 s1 to ku2¼ 0.189 s1 (p < 0.05).
These results suggest that the short-duration interactions
are relatively weak and brittle, since bond rupture was
accompanied by a short critical extension of the aIIbb3-
fibrinogen complex (xu1z 0.28 nm). By contrast, the
longer-duration interactions were more ductile and were
associated with an ~10-fold longer critical extension
(x¼ 2.46 nm), albeit with a stiff molecular spring (ksp¼
12 pN/nm). Nonetheless, the aIIbb3-fibrinogen complex ex-
isted predominantly in the weaker form and the overall
unbinding scenariowas similar to unbinding from theweaker
state. Because kinetic constants determined from single-
molecule unbinding assays and from bulk experiments are
different by nature, it is not possible to compare them
directly. Indeed, the kinetic parameters of forced dissociation
of the surface-bound molecules include their surface density,
steric limitations, and spatial orientation and should be
considered as pseudokinetic rate constants. However, the
parameters determined here may be more physiologically
relevant for in vivo platelet-matrix or platelet-platelet adhe-
sion mediated by fibrinogen and fibrin, where both the
receptor and the ligand are attached to a surface.
There are several potential explanations for the bimodal
mechanism of fibrinogen binding to aIIbb3. First, the
weaker and stronger binding states may correspond to two
different interconvertible functional states of the aIIbb3
molecule. This possibility is supported by the observation
that Mn2þ, a potent allosteric activator of aIIbb3, increases
the binding probability by shifting the aIIbb3 population
from the LR1 state to the LR2 state, as well as by recruiting
new aIIbb3 molecules from the available pool. Second, LR1
and LR2 may reflect sequential binding steps that differ in
the completeness of association and the depth of the
receptor-ligand docking. This possibility is corroborated
by our previous observation that the strength of integrin-
fibrinogen bonding is time-dependent (11), and by ligand-
induced binding-site remodeling in aIIbb3 (44). Based on
crystallographic observations (45), it is possible that the
fibrinogen gC-peptide initially binds to either aIIb or b3
as part of a ligand-binding claw (LR1), followed by attach-
ment to the rest of the aIIbb3 binding surface (LR2). Third,Biophysical Journal 100(1) 165–173
172 Litvinov et al.it is possible that there is more than one aIIbb3 binding site
on fibrinogen and that these binding sites interact coopera-
tively or synergistically (46). Thus, one of the two RGD
motifs in the fibrinogen Aa chain may form a transient
weak bond (LR1) that is reinforced by additional strong
bonds by the gC-peptide (LR2). The latter possibility can
be tested experimentally by using RGD- and AGDV-con-
taining peptides and/or a recombinant fibrinogen variant
with mutated potential aIIbb3-binding motifs.
Irrespective of the mechanisms underlying the existence
of two types of fibrinogen-aIIbb3 interactions, this finding
may have substantial physiological relevance. The short or
weak interactions may correspond to the so-called low-
affinity state of the aIIbb3 found on resting platelets.
Resting platelets adhere weakly and reversibly to fibrin-
ogen-coated surfaces, perhaps as a result of the short and
brittle aIIbb3-fibrinogen binding events we observed and
characterized in this study. However, when platelets,
and consequently aIIbb3, are activated and/or allowed to
stay in contact with fibrinogen for longer periods of time,
fibrinogen binding becomes strong and irreversible, perhaps
a reflection of the formation of a mechanically stable
aIIbb3-fibrinogen complex that is resistant to the pulling
forces generated by hydrodynamic shear. Remaining open
questions include whether the two types of aIIbb3-fibrin-
ogen interaction are interconvertible and what are the
driving forces for the strengthening of the interaction.
It has been hypothesized that integrin-ligand affinity and
unbinding kinetics could be modulated by an applied pulling
force, resulting in an initial increase in ligand-binding
affinity and bond lifetime at low forces (catch bonds) fol-
lowed by a decrease in affinity and bond lifetime at higher
forces (slip bonds). This hypothesis was based on a structural
model in which an applied force, by pulling on an inactive
integrin, opens its bent conformation and is followed by
a switchbladelike extension of the integrin into its active
form (25).
The only integrin shown to form bimolecular catch bonds
is a5b1 (28). We asked whether a catch-bond/slip-bond
mechanism could explain the interaction of aIIbb3 with
fibrinogen, as has been proposed by others (25–27). Because
the catch-bond regime occurs at tensile forces <30 pN (21–
23,47,48), we carried out constant-force measurements of
bond lifetimes for fibrinogen bound to aIIbb3 at several
pulling forces in the range 5–50 pN. We found that average
aIIbb3-fibrinogen bond lifetimes decreased monotonically
with increasing tensile force and did not exhibit biphasic
behavior indicative of pure slip-bond dissociation. More
complex model fitting also showed a gradual, monotonic
increase of the unbinding rate constants in response to
increasing unbinding force. Thus, within the 5–50 pN range
of constant pulling force, the aIIbb3-fibrinogen complex
does not form catch bonds, consistent with the lack of
shear-induced platelet adhesion on the fibrinogen-coated
surface over a wide range of shear forces (49). The resultsBiophysical Journal 100(1) 165–173also indicate that although the existence of two bound states
and/or two unbinding pathways is necessary for the emer-
gence of a catch regime of unbinding for biomolecular
complexes (50,51), this might not be sufficient for the
bond lifetimes to exhibit nonmonotonic biphasic depen-
dence on the applied pulling force.
In conclusion, we employed an optical-trap-based elec-
tronic force clamp and detected two types of aIIbb3-fibrin-
ogen complexes that differed in their mechanical stability, as
well as in their binding and unbinding kinetic pathways. We
found no evidence for catch bonds, consistent with the lack
of shear-enhanced platelet adhesion to fibrinogen-coated
surfaces. These observations provide important quantitative
and qualitative characteristics of fibrinogen binding and
unbinding to aIIbb3, events that underlie the dynamics of
fibrinogen-mediated platelet adhesion and aggregation in
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